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Abstract
Background: Soy consumption is associated with a lower incidence of colon cancer which is believed to be
mediated by one of its of components, genistein. Genistein may inhibit cancer progression by inducing apoptosis
or inhibiting proliferation, but mechanisms are not well understood. Epidermal growth factor (EGF)-induced
proliferation of colon cancer cells plays an important role in colon cancer progression and is mediated by loss of
tumor suppressor FOXO3 activity. The aim of this study was to assess if genistein exerts anti-proliferative properties
by attenuating the negative effect of EGF on FOXO3 activity.
Methods: The effect of genistein on proliferation stimulated by EGF-mediated loss of FOXO3 was examined in
human colonic cancer HT-29 cells. EGF-induced FOXO3 phosphorylation and translocation were assessed in the
presence of genistein. EGF-mediated loss of FOXO3 interactions with p53 (co-immunoprecipitation) and promoter
of p27kip1 (ChIP assay) were examined in presence of genistein in cells with mutated p53 (HT-29) and wild type
p53 (HCT116). Silencing of p53 determined activity of FOXO3 when it is bound to p53.
Results: Genistein inhibited EGF-induced proliferation, while favoring dephosphorylation and nuclear retention of
FOXO3 (active state) in colon cancer cells. Upstream of FOXO3, genistein acts via the PI3K/Akt pathway to inhibit
EGF-stimulated FOXO3 phosphorylation (i.e. favors active state). Downstream, EGF-induced disassociation of FOXO3
from mutated tumor suppressor p53, but not wild type p53, is inhibited by genistein favoring FOXO3-p53(mut)
interactions with the promoter of the cell cycle inhibitor p27kip1 in colon cancer cells. Thus, the FOXO3-p53(mut)
complex leads to elevated p27kip1 expression and promotes cell cycle arrest.
Conclusion: These novel anti-proliferative mechanisms of genistein suggest a possible role of combining genistein
with other chemoreceptive agents for the treatment of colon cancer.
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Background
Soy consumption is associated with a lower incidence of
cancer in Asian countries [1,2]. Although these
epidemiological studies are correlative, it has been
hypothesized that soy compounds may have anti-cancer
properties. Indeed numerous studies have shown a pro-
minent component of soy, genistein, has anticancer
properties [3-5], and the mechanism whereby genistein
exerts anticancer effects has been the subject of consid-
erable interest.
It has been shown that a synthetic analogue of the
genistein, phenoxodiol, significantly reduced colonic
tumor growth through inhibitory effects on the immune
system [6]. Genistein effectively suppresses the growth
of colon cancer cells [7] by attenuating activity of the
PI3K/Akt pathway [7-9], which is known to be critical
in the regulation of colon cancer progression [10,11].
Additionally, genistein affects the Wnt signaling pathway
in colon cancer cells, which is known to be important to
colon tumorigenesis [12] by inducing Wnt5a expression
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any medium, provided the original work is properly cited.[13]. Finally, a recent study demonstrated that in colon
cancer cells genistein affect the expression of estrogen
receptor and some tumor suppressor genes [14,15]
supporting a role of membrane receptors and tumor
suppressors in antiproliferative effects of genistein.
In human colon cancer EGF receptor (EGFR) expres-
sion and activity are increased [16,17], and targeting this
receptor has played an increasing therapeutic role [18].
We have demonstrated that proliferation of colon
cancer cells, stimulated with signals from EGFR, is
mediated by loss of tumor suppressor FOXO3 activity
[19]. EGF attenuates FOXO3 activity via the PI3K/Akt
pathway and results in loss of cell cycle arrest and
enhanced proliferation [19]. When activate (dephop-
shorylated), FOXO3 is localized in the nucleus and
binds to DNA or other transcriptional factors regulating
the expression of specific target genes involved in con-
trol of cell cycle progression, the mitotic program, or
induction of apoptosis [20]. The effect of genistein on
EGF-mediated loss of FOXO3 activity and associated
colon cell proliferation has not been determined. We
hypothesize that anti-proliferative properties of genistein
in colon cancer cells are mediated by inhibition of the
negative effect of EGF on FOXO3 activity, thus promot-
ing cell cycle arrest.
This study demonstrates a new anti-proliferative
mechanism of genistein mediated by inhibiting the nega-
tive effect of EGF on tumor suppressor FOXO3, which
favors the interaction of FOXO3 with mutated p53 in
colon cancer cells. The FOXO3-p53(mut) complex
binds to the promoter of p27kip1, causing increased
p27kip1 expression and subsequent induction of cell
cycle arrest in colon cancer cells. This is a novel anti-
proliferative mechanism and is relevant to designing
novel therapeutic agents, analogous to genistein, which
may be used to treat colon cancer.
Methods
Cell Culture
HT-29 colon cancer cells (American Type Culture Col-
lection (ATCC), Manassas, VA), carrying mutation in
tumor suppressor p53, and HCT116, with wild type p53,
w e r eg r o w ni nM c C o y ’s 5A medium (Sigma-Aldrich,
Saint Louis, MO) containing 10% FBS (Gibco) at 37°C
and 5% CO2. Monolayers were kept in McCoy’s5 A
media without serum for 20-24 h before experiments.
Treatment
To examine the effects of genistein on proliferation,
cells were incubated with 10-150 μM genistein (LC
L a b o r a t o r i e s ,W o b u r n ,M A )f o r4 8h o u r s .T oe x a m i n e
the effects of genistein on induced FOXO3 phosphoryla-
tion, translocation, interaction with p53, and binding to
p27kip1 promoter, monolayers were treated with EGF
(100 ng/ml) (Sigma-Aldrich) with and without mild con-
centration of genistein (50 μM) for 48 hours [21,22].
During EGF and genistein treatment, cells were placed
in serum-free and antibiotic-free medium.
Immunofluorescent Staining
To determine the inhibitory effect of genistein on EGF-
induced FOXO3 translocation from the nucleus to the
cytosol immunofluorescent staining was performed.
Monolayers were fixed with 3.7% paraformaldehyde and
permeabilized with 0.2% Triton X-100. For staining,
anti-FOXO3 primary antibody (Cell Signaling, Danvers,
MA) and Alexa 488 conjugated secondary antibody were
used (Molecular Probes-Invi t r o g e n ,C a r l s b a d ,C A ) ,a s
previously described [19,23,24]. After washing with PBS,
coverslips were mounted using Prolong Gold antifade
reagent (Molecular Probes), and images were captured
with a Nikon Confocal Microscope C1 and analyzed
with EZ-C1 software (Nikon, Tokyo, Japan).
Protein Extraction
Total protein was extracted using a lysis buffer (Cell
Signaling, Danvers, MA) with a protease inhibitor cock-
tail (Sigma-Aldrich), and protein concentration was
determined by Bradford assay (Bio-Rad, Hercules, CA).
The protein extracts were stored at -20°C until further
processing.
Immunoblot
Equal amounts of protein (40 μg) were separated by
SDS-PAGE and transferred to nitrocellulose membranes
by voltage gradient transfer (Bio-Rad). Prepared blots
were blocked and detection was performed using speci-
fic antibodies for total FOXO3 (Cell Signaling Technol-
ogy, Danvers, MA), phosphorylated FOXO3 at Thr 32
(Upstate Biotechnology), pAkt (Cell Signaling), p27kip1
(Cell Signaling), actin, EGFR, pEGFR, and p53 (Santa
Cruz Biotechnology, Santa Cruz, CA). After washing,
the blots were incubated with horseradish peroxidase
linked secondary antibodies (Cell Signaling, Danvers,
MA), and detection was achieved with ECL plus western
blotting detection reagents (GE Healthcare, Buckin-
ghamshire, United Kingdom). Intensity of the bands was
quantified by optical densitometry using Labworks 4.6
Image Acquisition and Analysis Software (UVP, Cam-
bridge, UK), and was calculated as percentage of
changes relative to control.
Co-Immunoprecipitation
The effect of genistein on FOXO3-p53 incitation was
assessed by co-immunoprecipitation. One milligram of
whole cell lysate was incubated with 10 μgo fm o u s e
anti-FOXO3 antibody (Cell Signaling) and protein A
beads overnight at 4°C. Immunoprecipitates were
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PAGE, and transferred to membranes. Immunoblot analy-
sis was performed with anti-p53 antibody from rabbit
(Santa Cruz Biotechnology) to prevent cross-reaction. IgG
antibody from mouse was used as a negative control.
Chromatin Immunoprecipitation (ChIP) Assay
The effect of genistein on FOXO3 binding to p27kip1
promoter was examined by ChIP assay according to the
manufacturer’s instructions (Millipore, Temecula, CA).
After cross-linking with 1% formaldehyde, the cells were
incubated in lysis buffer and sonicated to cut DNA (200
to 1000 bp). Aliquots (20 μl) from each sample were
held separately for use as “input DNA” in PCR analysis.
Equal amounts of protein were incubated with FOXO3
(Cell Signaling) or p53 (Santa Cruz) antibodies at 4°C
overnight, and the complexes comprised of DNA-pro-
tein were pelleted with protein G-agarose. After rever-
sing the immunoprecipitated complexes and input
aliquots with 5 M NaCl at 65°C for 4 hours, protein was
separated from DNA using proteinase K. Extracted
DNA (phenol/chloroform) was amplified using primers
from p27kip1 promoter (forward: 5’-GTC CCT TCC
AGC TGT CAC AT-3’;r e v e r s e ,5 ’-GGA AAC CAA
CCT TCC GTT CT-3’). Input represents PCR amplifica-
tion of DNA from cell lysate before immunoprecipita-
tion with the primers used to amplify the p27kip1
promoter and b-actin (forward, 5’-CCA CAC TGT GCC
CAT CTA CG-3’; reverse, 5’- AGG ATC TTC ATG
AGG TAG TCA GTC AG-3’).
Cell Proliferation Assays
An inhibitory effect of genistein on proliferation of
colon cancer cell lines was detected using the MTS
assay (Promega; Medison, WI). Cells grown in regular
media were plated on 96-well plates (5000 cells per
well) and after 48 hours of incubation with the experi-
mental compounds, part of the medium was removed,
and MTS solution was added for another 3 hours at 37°
C. A water-soluble formazan product converts from
MTS and was detected at 490 nm using a SPECTRA-
max Plus Microplate Reader (Molecular Devices, Sunny-
vale, CA). Results obtained at 490 nm were converted to
percentile changes relative to control.
siRNA
Silencing p53 (siRNA) was utilized to determine its
effect on FOXO3 activity in HT-29 cells. Cells were
transfected with p53 siRNA (Santa Cruz Biotechnology)
(GCAUGAACCGGAGGCCCAU) or negative-control
(Invitrogen) using Lipofectamine RNAiMAX (Invitro-
gen). After 5 hours, transfection media was replaced
with regular media containing genistein and protein was
extracted 48 hours later.
Statistical Analysis
Data were compared by a one-way analysis of variance
and a Student’s t test. The results are expressed as
means ± standard deviation. Differences were considered
significant at p < 0.05.
Results
Genistein inhibits EGF-induced proliferation, FOXO3
phosphorylation, and translocation in colon cancer cells
EGF promotes proliferation and is known to be critical
to the progression of colon cancer [16-18]. Anti-prolif-
erative properties of genistein, exerted by targeting dif-
ferent kinases of various proliferative pathways [9,25-28]
were assessed on EGF-induced proliferation in colon
cancer cells. EGF-induced proliferation of HT-29 cells
was inhibited by genistein (Figure 1A), suggesting that
genistein may affect the EGF pathway in colon cancer
cells. We previously demonstrated that EGF-induced
proliferation is mediated via loss of tumor suppressor
FOXO3 activity [19]. In the presence of genistein, EGF-
induced FOXO3 phosphorylation at Thr32 (inactivation)
[19] was inhibited (Figure 1B), showing that genistein
promotes FOXO3 activity. Active FOXO3 localizes to
the nucleus and following phosphorylation by EGF,
FOXO3 translocates to the cytosol [19]. Genistein inhib-
ited EGF-induced FOXO3 translocation to the cytosol,
and thus FOXO3 remained in the nucleus (Figure 1C).
Moreover, the high basal level of phosphorylated
FOXO3 (inactive) in sub-confluent HT-29 cells was sig-
nificantly diminished by genistein (Figure 1D), further
supporting that genistein promotes FOXO3 activity in
proliferative colon cancer cells regardless of EGF stimu-
lation. These data suggested that attenuation of EGF-
induced proliferation by genistein is in part mediated by
inhibition of FOXO3 phosphorylation (inactivation) and
translocation to the cytosol in colon cancer cells (i.e.
FOXO3 inactivation).
Genistein inhibition of EGF-induced FOXO3
phosphorylation is mediated by the PI3K/Akt pathway
The above data show that genistein inhibits EGF-
induced FOXO3 phosphorylation at Thr32, which is
known to be a PI3K/Akt specific site [19]. Since PI3K/
A k ti sd o w n s t r e a mo fE G F R ,w es o u g h tt oe x a m i n e
whether genistein targets the EGFR or the PI3K/Akt
pathway. Although genistein modestly increases basal
pEGFR (at Ser1070), it did not affect expression and
phosphorylation of the EGFR during EGF treatment
(Figure 2A). Additionally, an EGF-induced 4-fold
increase in Akt phosphorylation was diminished by gen-
istein (Figure 2B). Also, genistein insignificantly
decreased the basal level of pAkt. Thus we speculate
genistein inhibits EGF-induced FOXO3 phosphorylation
via the PI3K/Akt pathway.
Qi et al. BMC Cancer 2011, 11:219
http://www.biomedcentral.com/1471-2407/11/219
Page 3 of 9Genistein inhibits EGF-induced FOXO3 disassociation from
the promoter of p27kip1 cell cycle inhibitor
Downstream, EGF treatment led to FOXO3 disassocia-
tion from the promoter for the cell cycle inhibitor
p27kip1 [19]. Thus we assessed if genistein inhibits pro-
liferation by preventing EGF-induced FOXO3 disasso-
ciation from p27kip1 promoter. In HT-29 cells genistein
increased p27kip1 expression 2-fold (Figure 3A) and
ChIP assay revealed that genistein inhibits EGF-induced
FOXO3 disassociation from p27kip1 promoter (Figure
3B). Thus, we speculate that genistein promotes FOXO3
binding to the p27kip1 promoter, increasing p27kip1
expression, and ultimately leading to cell cycle arrest in
colon cancer cells. Next, we sought to determine the
mechanism whereby genistein promotes FOXO3 binding
to the p27kip1 promoter.
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Figure 1 Genistein inhibits EGF-induced proliferation and FOXO3 phosphorylation and translocation in colon cancer cells. (A) HT-29
cells were stimulated with EGF in presence of genistein (10, 50, 100, and 150 μM) and assayed for proliferation 48 hours later by MTS. This
experiment was repeated three independent times and graphed data are mean ± sd (n = 24, *p < 0.001). (B) Genistein inhibits EGF-induced
FOXO3 phosphorylation. HT-29 cells treated with EGF, with and without genistein, were examined for phosphorylated FOXO3 at Thr32. Genistein
inhibits EGF induced FOXO3 phosphorylation. Immunoblots were performed three independent times and graphs represent densitometric
analysis means ± sd (n = 3, *p < 0.05). (C) Genistein inhibits EGF-induced translocation of FOXO3. Immunofluorescent staining of experimental
monolayers revealed that EGF-induced FOXO3 translocation from the nucleus to the cytosol was inhibited by genistein. This experiment was
repeated two times in triplicate. (D) Genistein inhibits FOXO3 phosphorylation in colon cancer cells. Equal amounts of protein extracted from
70% confluent (proliferative) and 100% confluent HT-29 monolayers were separated and immunoblotted with antibodies against phosphorylated
FOXO3, total FOXO3, and actin. In proliferative HT-29 cells (70% confluent), the phosphorylated form of FOXO3 is increased relative to non-
proliferative cells (100% confluent). HT-29 cells (70% confluent) were incubated with genistein for 24 hours and the status of phosphorylated
FOXO3 was examined. Genistein attenuates phosphorylated FOXO3 in sub-confluent HT-29 cells. These experiments were repeated three times
and graphs represent densitometric analysis (n = 8, *p < 0.05).
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Page 4 of 9Genistein inhibits EGF-mediated disassociation of FOXO3
from p53(mut) tumor suppressor
Transcriptional activity of FOXO3 could be modulated
though interactions with other transcriptional factors
such as tumor suppressor p53 [29], which is known to be
mutated in some colonic cancers and is critical to cancer
progression [30-33]. We assessed if genistein affects
interactions of FOXO3 with mutated p53, thus further
affecting FOXO3 activity. Genistein increases expression
of mutated p53 by 2.5-fold in HT-29 cells (Figure 4A),
and co-immunoprecipitation demonstrated an increased
interaction of p53(mut) with FOXO3 (Figure 4B). More-
over, co-immunoprecipitation shows that the FOXO3-
p53(mut) complex is diminished during EGF treatment,
while genistein reduces the effect of EGF (Figure 4C).
Next, we assessed if FOXO3-p53 interactions are specific
for mutated p53 using colonic HCT116 cells with wild
type p53. In HCT116 cells, although FOXO3-p53 com-
plex was found, EGF and genistein did not affect this
interaction (Figure 4D), supporting that the interaction
of FOXO3 with mutated p53 is targeted by genistein.
Taken together these data show that the interaction
between p53 and FOXO3, which is impaired by EGF, is
promoted by genistein in HT-29 cells.
Genistein mediated FOXO3 and p53(mut) interaction
promotes FOXO3 activity on p27kip1 promoter
The above data support that genistein increases FOXO3
binding to the p27kip1 promoter and also favors
FOXO3 interactions with p53(mut). However, the
p27kip1 promoter did not show putative p53 binding
sites (GGACATGCCCGGGCATGTCC) [34,35] in the
-200 bp regions where the FOXO3 binding site is
located (-110 bp). Thus, we hypothesized that the
FOXO3-p53(mut) complex could be found on the
FOXO3 binding site of p27kip1 promoter. Using ChIP
assay, performed by immunoprecitating protein-DNA
complex with anti-p53 antibody, p53 was found to be
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Figure 2 Genistein inhibits FOXO3 phosphorylation via PI3K/
Akt. Total protein from HT-29 cells (control and EGF treated for 30
minutes) was examined for phosphorylated (A) EGFR and (B) Akt in
the presence and absence of genistein. Genistein inhibits EGF
induced Akt phosphorylation in HT-29 cells. The experiment was
repeated in triplicate and graphs represent densitometric analysis (n
= 3, *p < 0.05).
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Figure 3 Genistein increases p27kip1 expression and promotes
FOXO3 binding to the p27kip1 promoter. (A) Protein from
control and genistein treated HT-29 cells was separated and
immunoblotted for p27kip1. Immunoblots revealed that genistein
increased p27kip1. The experiment was performed three
independent times and quantified using densitometry (n = 3, *p <
0.05). (B) Genistein inhibits FOXO3 disassociation from p27kip1
promoter. ChIP assay was performed to determine FOXO3 binding
to p27kip1 promoter (-110 bp). EGF-induced FOXO3 disassociation
from p27kip1 promoter (-110 bp) was inhibited by genistein. Input
represents PCR amplification of DNA from cell lysate prior to
immunoprecipitation with the primers from p27kip1 promoter. This
experiment was repeated two times.
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Page 5 of 9present in the p27kip1 promoter within the FOXO3
binding region (Figure 5A). In HT-29 cells with silent
p53, genistein did not increase p27kip1 expression
(Figure 5B), supporting that p53(mut) positively regu-
lates FOXO3 activity in the FOXO3-p53(mut) complex.
The genistein-stimulated interaction between p53 and
FOXO3 promotes FOXO3 activity and resistance to
EGF, thus increasing expression of the p27kip1 cell
cycle inhibitor (Figure 6).
Discussion
Genistein, a predominant component of soy products,
has been shown to have anti-cancer properties [2,3,5].
This study revealed a novel mechanism that genistein
utilizes to inhibit proliferation. Proliferation of EGF trea-
ted colon cancer cells is mediated by loss of FOXO3
activity [19], and here we showed this pathway to be
inhibited by genistein. Upstream, genistein inhibits EGF
induced loss of FOXO3 activity by targeting the PI3K/
Akt pathway. Downstream, genistein inhibits EGF-
induced FOXO3 disassociation from p53(mut), which
further promotes FOXO3 activity and leads to increased
expression of the p27kip1 cell cycle inhibitor, which
inhibits proliferation in colon cancer cells.
We demonstrated that one of the anti-proliferative
mechanisms of genistein in colon cancer cells is to pro-
mote FOXO3 activity by inhibiting EGF-induced
FOXO3 phosphorylation (inactivation) via the PI3K/Akt
pathway. Active FOXO3 negatively regulates prolifera-
tion of colon cancer cells [36], and we showed that its
inactivation is an essential step in EGF-mediated prolif-
eration [19]. Although some studies demonstrated that
high concentrations of genistein can downregulate
EGFR in prostate cells [37], we showed that the concen-
tration of genistein used for this study did not affect
EGFR expression in colon cancer cells and had modest
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independent times and quantified using densitometry (n = 3, *p <
0.05). (B, C) Protein from different experimental groups from HT-29
cells was immunoprecipitated with antibody against FOXO3
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Co-immunoprecipitation revealed that genistein increased FOXO3-
p53(mut) interaction and prevented EGF induced disassociation of
p53 and FOXO3. IgG (mouse) was used as a negative control.
Experiments were repeated three times. (D) Protein from HCT116
with wild type p53 was immunoprecipitated with anti-FOXO3
(mouse) and immunoblotted using antibody against p53 (rabbit).
Nether EGF nor genistein affected FOXO3 interaction with wild type
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Figure 5 The FOXO3-p53(mut) complex promotes p27kip1
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specific. It has been shown that genistein inhibits EGF-
stimulated serine, threonine, and tyrosine phosphoryla-
tion [38]. Also, genistein affects estrogen receptors [39],
which are critical in colon cancer progression [14].
Therefore, we speculate, that genistein inhibit Akt inde-
pendently of EGFR, by attenuating either kinase activity
downstream of EGFR or blocking estrogen receptor. It
has been previously demonstrated that genistein inhibits
proliferation in colon cancer cells via PI3K/Akt [40], a
pathway known to be critical to colon cancer progres-
sion [10,11,41], however downstream mechanisms were
not well understood. This study demonstrated that gen-
istein inhibits PI3K/Akt activation that leads to preven-
tion of FOXO3 phosphorylation (inactivation) in colon
cancer cells and revealed a new mechanism whereby
genistein attenuates proliferation of colon cancer cells.
Active FOXO3 attenuates proliferation by upregula-
tion of the cell cycle inhibitor p27kip1 [36,42], and we
showed that EGF-induced FOXO3 disassociation from
the p27kip1 promoter [19] is inhibited by genistein in
colon cancer cells. In prostate and breast cancer cells,
the anti-proliferative effects of genistein occur by
increasing levels of the cell cycle inhibitor p27kip1
[43,44], but upstream mechanisms were not understood.
Here we showed that genistein increases p27kip1
expression in colon cancer cells by promoting FOXO3
binding to the p27kip1 promoter. It is important to take
into account that increased p27kip1 by genistein is most
likely one of the mechanisms of inhibition of prolifera-
tion and that the other targeted molecules also play a
role. Also, this study demonstrated that for increased
p27kip1 expression, interaction between FOXO3 and
mutated tumor suppressor p53 is required. In contrast
to human lung cancer cells where genistein increased
wild type but not mutated p53 [45], in colon cancer
HT-29 cells we showed that genistein increased expres-
sion of mutated p53. Although, wild type p53 interacts
with FOXO3 thereby decreasing its activity in the
FOXO3-53 complex [29,46,47], this study demonstrated
that mutated p53 increased FOXO3 activity in HT-29
cells. Additionally EGF treatment did not affect
interactions between wild type p53 and FOXO3 further
supporting that a mutation of p53 is most likely accoun-
table for the genistein effect. Since a mutation of p53 is
critical to colon cancer development [30-33], the anti-
proliferative properties of genistein may relate to target-
ing mutated p53 and thus promoting FOXO3 activity
and cell cycle arrest.
This study showed that genistein inhibits proliferation
of colon cancer cells by attenuating a negative effect of
EGF on tumor suppressor FOXO3 activity, thereby pro-
moting FOXO3 interaction with mutated p53, which
leads to expression of p27kip1 and cell cycle arrest.
These findings support a potential role of genistein in
combination with other chemopreventive agents
[3,48,49] for the treatment of colon cancer.
Conclusion
Genistein inhibits EGF-induced proliferation in colon
cancer cells by promoting FOXO3 activity, targeting
upstream the PI3K/Akt pathway, and stimulating down-
stream FOXO3 interaction with tumor suppressor
p53mut. As a result of increased FOXO3 activity,
expression of p27kip1 is elevated, which leads to cell
cycle arrest. This is a new anti-proliferative mechanism
for genistein and sets the foundation for the potential
combined use of genistein with other chemoreceptive
agents in the treatment of colon cancer.
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